Payer perspectives on health technology assessment

摘要

The payer survey reported by Leung et al. in this issue of JMCP provides a baseline cross-sectional analysis for the Academy of Managed Care Pharmacy/ National Pharmaceutical Council/International Society for Pharmacoeconomics and Outcomes Research (AMCP/NPC/ ISPOR) Comparative Effectiveness Research Collaborative Initiative (CER-CI).1 The goal of CER-CI is to establish a consensus-based set of principles and tools to guide the design and evaluation of nonexperimental studies, including prospective and retrospective observational designs, so that the knowledge gained from these studies can be applied to improve patient health outcomes.2 Health care reform has set the stage for this dialogue, and to best use the opportunity, participants need to understand how payers that assess pharmaceutical technology currently view observational study designs and which factors affect their credibility for this audience.